Rakovina Therapeutics Inc. (RKV.V)
| Previous Close | 0.1650 |
| Open | 0.1500 |
| Bid | 0.1250 x N/A |
| Ask | 0.1500 x N/A |
| Day's Range | 0.1500 - 0.1500 |
| 52 Week Range | 0.1200 - 0.3000 |
| Volume | |
| Avg. Volume | 12,747 |
| Market Cap | 10.474M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0430 |
| Earnings Date | May 26, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Rakovina Therapeutics Announces Results from Annual General Meeting
VANCOUVER, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the results of voting at its 2022 Annual General Meeting of Shareholders held on June 23, 2022 (the “Meeting”). All four members of the Company’s Board of Directors named as nominees in its management information circular (the “Circular”
- Newsfile
Rakovina Therapeutics: Transform & Extend the Lives of Patients with Cancer, CEO Clip Video
Vancouver, British Columbia--(Newsfile Corp. - May 27, 2022) - Rakovina Therapeutics Inc. (TSXV: RKV) - The biotechnology company is developing precision medicines that selectively target and kill cancer cells using leading-edge science to discover and advance innovative cancer treatments with the potential to improve patient outcomes across multiple tumor types.If you cannot view the video above, please visit:https://b-tv.com/rakovina-therapeutics-transform-extend-the-lives-of-patients-with-can
- GlobeNewswire
Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, announced the financial results for the quarter ended March 31, 2022 and provided a corporate update. “This quarter marks the first year of operations for Rakovina Therapeutics, Inc. which initiated activity in March 2021,” said Mr. Jeffrey Bacha executive chai
